Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer
Cancer Letters · 2026-05 · 645 · 218356
DOI: 10.1016/j.canlet.2026.218356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-05. Verfasst von Yidan Chen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hangzhou Cancer Institute, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, …. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Lung Neoplasms, Protein Kinase Inhibitors, Organoids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Science and Technology Project of Zhejiang Province, Hangzhou Municipal Health Commission, Hangzhou Science and Technology Commission.
Abstract (Originalsprache)
Lung cancer remains the leading cause of cancer-related mortality and drug resistance represents a major challenge in treatment. However, the scarcity of models that faithfully recapitulate the features of lung cancer has hindered advances in understanding drug resistance mechanisms and developing precision therapies. To address these challenges, we devised an optimized protocol that coupled Ficoll density-gradient separation with low-adhesion culture conditions, constructing 48 organoids from 58 malignant effusion (ME) samples, with a success rate of 82.8%. Further drug sensitivity experiments demonstrated that the patient-derived organoid (PDO) model could effectively predict responses to clinical treatment, with a specificity of 91.7%, sensitivity of 71.4%, and overall accuracy of 87.1%. Transcriptomic analysis of PDOs identified that the key signal pathways, including extracellular matrix remodeling, cell cycle dysregulation and angiogenesis, were involved in the resistance mechanisms of third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Connectivity Map (CMap) screening revealed that the candidate ibuprofen could enhance the anti-tumor activity of osimertinib and overcome the resistance, validated in PDO and TKI-resistant lung cancer cell models. These findings not only provide a new biological perspective for the study of EGFR-TKI resistance mechanisms but also offer a novel tool and strategy for precision treatment and personalized drug screening in advanced lung cancer patients, with significant clinical application potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hangzhou Cancer Institute, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
- Hangzhou Cancer Institute, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China; Department of R&D, Hangzhou AimingMed Technologies Co., Hangzho…
- Department of Thoracic Oncology, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
- Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
- Department of Pathology, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
- Basic Medicine School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Förderung
- Medical Science and Technology Project of Zhejiang Province
- Hangzhou Municipal Health Commission
- Hangzhou Science and Technology Commission
Zitieren
APA
Chen, Y., Xing, H., Yang, X., Shen, J., Jiang, W., Huang, J., Qiu, Y., Li, X., Wu, K., Yang, S., Zhu, L., Zhou, R., Shen, C., Ma, S., You, M., Xia, B., & Chen, X. (2026). Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer. Cancer Letters, 645, 218356. https://doi.org/10.1016/j.canlet.2026.218356
Vancouver
Chen Y, Xing H, Yang X, Shen J, Jiang W, Huang J, et al. Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer. Cancer Letters. 2026;645:218356. doi:10.1016/j.canlet.2026.218356
BibTeX
@article{Chen2026,
author = {Chen, Yidan and Xing, Huayang and Yang, Xinyu and Shen, Juan and Jiang, Wangyue and Huang, Jie and Qiu, Yao and Li, Xi and Wu, Kan and Yang, Shaoyu and Zhu, Lucheng and Zhou, Rongjing and Shen, Chongyang and Ma, Shenglin and You, Mingliang and Xia, Bing and Chen, Xueqin},
title = {Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer},
journal = {Cancer Letters},
year = {2026},
volume = {645},
pages = {218356},
doi = {10.1016/j.canlet.2026.218356}
}
EUVIMED